<DOC>
	<DOCNO>NCT01163227</DOCNO>
	<brief_summary>This PoC study design assess cognitive effect dose AQW051 patient chronic stable schizophrenia .</brief_summary>
	<brief_title>Effect AQW051 Cognitive Function Patients With Chronic Stable Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>1 . Diagnosis schizophrenia 2 . Symptomatically stable currently treat stable regimen least 3 ( three ) month prior dose one follow second generation antipsychotic : risperidone , paliperidone , quetiapine , ziprasidone , aripiprazole . 3 . Specific cognitive impairment 4 . Smokers nonsmoker 1 . Current treatment anticholinergic agent know adversely interfere cholinergic system , and/ treatment cholinesterase inhibitor within last three ( 3 ) month prior dose . 2 . Current treatment conventional antipsychotic ( e.g fluphenazine , haloperidol ) clozapine . 3 . History neuroleptic malignant syndrome . 4 . Diagnosis substance abuse ( nicotine ) within last month alcohol substance dependence ( nicotine ) within last 6 month . 5 . Any clinically significant suicidal ideation ( Type 4 5 ColumbiaSuicide Severity Rating Scale ( CSSRS ) last month ) previous history suicide behavior Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Hallucinations ,</keyword>
	<keyword>psychotic ,</keyword>
	<keyword>delusion ,</keyword>
	<keyword>cognitive deficit</keyword>
</DOC>